Decoding Human Fetal Liver Haematopoiesis
Oct 9, 2019·,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,·
0 min read
D. m. popescu
R. a. botting
E. stephenson
K. green
S. webb
L. jardine
E. f. calderbank
K. polanski
I. goh
M. efremova
M. acres
D. maunder
P. vegh
Y. gitton
J. e. park
R. vento tormo
Z. miao
D. dixon
R. rowell
D. mcdonald
J. fletcher
E. poyner
G. reynolds
M. mather
C. moldovan
L. mamanova
F. greig
M. d. young
K. b. meyer
S. lisgo
J. bacardit
A. fuller
B. millar
B. innes
S. lindsay
M. j. t. stubbington
M. s. kowalczyk
Dr. Bo Li
O. ashenberg
M. tabaka
D. dionne
T. l. tickle
M. slyper
O. rozenblatt rosen
A. filby
P. carey
A. c. villani
A. roy
A. regev
A. chedotal
I. roberts
B. gottgens
S. behjati
E. laurentidagger
S. a. teichmanndagger
M. haniffadagger
Abstract
Definitive haematopoiesis in the fetal liver supports self-renewal and differentiation of haematopoietic stem cells and multipotent progenitors (HSC/MPPs) but remains poorly defined in humans. Here, using single-cell transcriptome profiling of approximately 140,000 liver and 74,000 skin, kidney and yolk sac cells, we identify the repertoire of human blood and immune cells during development. We infer differentiation trajectories from HSC/MPPs and evaluate the influence of the tissue microenvironment on blood and immune cell development. We reveal physiological erythropoiesis in fetal skin and the presence of mast cells, natural killer and innate lymphoid cell precursors in the yolk sac. We demonstrate a shift in the haemopoietic composition of fetal liver during gestation away from being predominantly erythroid, accompanied by a parallel change in differentiation potential of HSC/MPPs, which we functionally validate. Our integrated map of fetal liver haematopoiesis provides a blueprint for the study of paediatric blood and immune disorders, and a reference for harnessing the therapeutic potential of HSC/MPPs.
Type
Publication
Nature
Authors
Authors
Authors
Authors
Authors
Authors
Authors
Authors
Authors
Authors
Authors
Authors
Authors
Authors
Authors
Authors
Authors
Authors
Authors
Authors
Authors
Authors
Authors
Authors
Authors
Authors
Authors
Authors
Authors
Authors
Authors
Authors
Authors
Authors
Authors
Authors
Authors

Authors
Principal Scientist II
Dr. Bo Li is a Principal Scientist at Genentech, Inc. His research focuses on large-scale single-cell genomics data analysis.
Before joining in Genentech, he was an Assistant Professor of Medicine at Harvard Medical School and the director of Bioinformatics and Computational Biology at Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital.
He received his Ph.D. in computer science from UW-Madison and completed two postdoctoral trainings with Dr. Lior Pachter at UC Berkeley and Dr. Aviv Regev at Broad Institute.
He is best known for developing RSEM, an impactful RNA-seq transcript quantification software. RSEM is cited 22,602 times (Google Scholar) and adopted by several big consortia such as TCGA, ENCODE, GTEx and TOPMed.
Authors
Authors
Authors
Authors
Authors
Authors
Authors
Authors
Authors
Authors
Authors
Authors
Authors
Authors
Authors
Authors
Authors
Authors